(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on Alcon with a price target lowered from 88 to 83.8 Swiss francs, a new target that harbors a potential upside of 28% for the title of the ophthalmology laboratory .
“Concerns about margin targets being achievable and short-term and minor weakness in contact lenses have led to a 10% drop in the share price”, points out the broker, who sees this correction as an opportunity of purchase.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
